Do Visible Residue Limits Make the 10-ppm Carryover Limit Obsolete? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Do Visible Residue Limits Make the 10-ppm Carryover Limit Obsolete?
The author discusses how the use of a visible residue limit has made the 10-ppm cleaning limit obsolete in many applications.


Pharmaceutical Technology
Volume 34, Issue 2, pp. 60-63

References

1. K.M. Jenkins and A.J. Vanderwielen, Pharm. Technol., 18 (4), 60–73 (1994).

2. R. J. Forsyth and D. Haynes, Pharm. Technol., 22 (9), 104– 112 (1998).

3. D. A. LeBlanc, D. D. Danforth, and J. M. Smith, Pharm. Technol., 17 (10), 118–1124 (1993).

4. B. D. Naumann and P. A. Weideman, Human Ecol. Risk Assess. 1 (5), 590–613 (1995).

5. B. D. Naumann and E. V. Sargent, Occup. Med. 12 (1), 33–42 (1996).

6. G. L. Fourman and M. V. Mullen, Pharm. Technol., 17 (4), 54–60 (1993).

7. R. J. Forsyth, A. LeBlanc, and M. Voaden, Pharm. Technol., 31 (1), 74- 83 (2007).

8. FDA, "Guide to Inspection of Validation of Cleaning Processes" (Rockville, MD, July 1993).

9. Health Canada, "Cleaning Validation Guidelines" (June 2002).

10. PIC/S, Recommendation on Validation Master Plan, Installation and Operational Qualification, Non-sterile Process Validation, Cleaning Validation (PI 006-2, July 2004).

11. EudraLex, "Qualification and Validation" (Annex 15, July 2001).

12. M. Lazar, Pharm. Technol., 21 (9), 56–73 (1997).

13. D. A. LeBlanc, PDA J. Pharm. Sci. and Technol., 56 (1), 31–36 (2002).

14. J.M. Cardot and E. Beyssac, Cont. Environ., 11 (6), 11–14 (2008).

15. R. J. Romanach et. al., Pharm. Technol., 23 (1), 46–58 (1999).

16. M. C. Oliver, Eur. J. Parent. Sci., 5 (4), 97–100 (2000).

17. J. E. Martinez, Pharm. Technol., 26 (11), 62–74 (2002).

18. R. J. Forsyth and V. Van Nostrand, Pharm. Technol., 28 (10), 58–72 (2004).

19. R. J. Forsyth and V. Van Nostrand, Pharm. Technol., 29 (10), 152– 161 (2005).

20. R.J. Forsyth et al., Pharm. Technol., 30 (11), 90–100 (2006).

21. R.J. Forsyth, Pharm. Technol., 33 (3), 102–111 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here